請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40278完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李伯皇 | |
| dc.contributor.author | Chin-Sheng Hung | en |
| dc.contributor.author | 洪進昇 | zh_TW |
| dc.date.accessioned | 2021-06-14T16:43:54Z | - |
| dc.date.available | 2009-09-11 | |
| dc.date.copyright | 2008-09-11 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-31 | |
| dc.identifier.citation | Akekawatchai, C., Holland, J. D., Kochetkova, M., Wallace, J. C., and McColl, S. R. (2005). Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 280, 39701-39708.
Altundag, K., Morandi, P., Altundag, O., and Gunduz, M. (2005). Possible role of CXCR4-mediated chemotaxis in breast cancer patients with central nervous system metastases. Breast Cancer Res Treat 89, 317. Arya, M., Patel, H. R., McGurk, C., Tatoud, R., Klocker, H., Masters, J., and Williamson, M. (2004). The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 4, 291-303. Balkwill, F. (2004). The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14, 171-179. Bernards, R. (2003). Cancer: cues for migration. Nature 425, 247-248. Cabioglu, N., Sahin, A., Doucet, M., Yavuz, E., Igci, A., E, O. Y., Aktas, E., Bilgic, S., Kiran, B., Deniz, G., and Price, J. E. (2005a). Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 22, 39-46. Cabioglu, N., Yazici, M. S., Arun, B., Broglio, K. R., Hortobagyi, G. N., Price, J. E., and Sahin, A. (2005b). CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11, 5686-5693. Cheng, X., and Hung, M. C. (2007). Breast cancer brain metastases. Cancer Metastasis Rev 26, 635-643. Colleoni, M., O'Neill, A., Goldhirsch, A., Gelber, R. D., Bonetti, M., Thurlimann, B., Price, K. N., Castiglione-Gertsch, M., Coates, A. S., Lindtner, J., et al. (2000). Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 18, 3925-3935. Cunnick, G. H., Jiang, W. G., Douglas-Jones, T., Watkins, G., Gomez, K. F., Morgan, M. J., Subramanian, A., Mokbel, K., and Mansel, R. E. (2008). Lymphangiogenesis and lymph node metastasis in breast cancer. Mol Cancer 7, 23. Darash-Yahana, M., Pikarsky, E., Abramovitch, R., Zeira, E., Pal, B., Karplus, R., Beider, K., Avniel, S., Kasem, S., Galun, E., and Peled, A. (2004). Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18, 1240-1242. Dewan, M. Z., Ahmed, S., Iwasaki, Y., Ohba, K., Toi, M., and Yamamoto, N. (2006). Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 60, 273-276. Ellis, C. M., Dyson, M. J., Stephenson, T. J., and Maltby, E. L. (2005). HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 58, 710-714. Fidler, I. J. H., I. R. (1982). Biological diversity in metastatic neoplasms: origins and implications Science 217, 998-1003. Figueroa, J. A., Yee, D., and McGuire, W. L. (1993). Prognostic indicators in early breast cancer. Am J Med Sci 305, 176-182. Hall, J. M., and Korach, K. S. (2003). Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17, 792-803. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. Hao, L., Zhang, C., Qiu, Y., Wang, L., Luo, Y., Jin, M., Zhang, Y., Guo, T. B., and Matsushima, K. (2007). Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett 253, 34-42. Hermanek, P., Hutter, R. V., Sobin, L. H., and Wittekind, C. (1999). International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86, 2668-2673. Holm, N. T., Byrnes, K., Li, B. D., Turnage, R. H., Abreo, F., Mathis, J. M., and Chu, Q. D. (2007). Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 141, 53-59. Hoon, D. S., Kitago, M., Kim, J., Mori, T., Piris, A., Szyfelbein, K., Mihm, M. C., Jr., Nathanson, S. D., Padera, T. P., Chambers, A. F., et al. (2006). Molecular mechanisms of metastasis. Cancer Metastasis Rev 25, 203-220. http://www.doh.gov.tw/ufile/doc/我國主要癌症死亡原因.xls (2007). 行政院衛生署統計資料. In, 行政院衛生署, ed. (Taiwan). Kang, H., Mansel, R. E., and Jiang, W. G. (2005a). Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int J Oncol 26, 1429-1434. Kang, H., Watkins, G., Douglas-Jones, A., Mansel, R. E., and Jiang, W. G. (2005b). The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 14, 360-367. Kato, M., Kitayama, J., Kazama, S., and Nagawa, H. (2003). Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5, R144-150. Kulka, J., Tokes, A. M., Kaposi-Novak, P., Udvarhelyi, N., Keller, A., and Schaff, Z. (2006). Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res 12, 197-204. Lechertier, T., Berard, M., Vassy, R., Herve, M. A., and Crepin, M. (2004). Transendothelial migration of two metastatic breast carcinoma cells depend on the SDF-lalpha-CXCR4 complexes. Anticancer Res 24, 4011-4017. Li, Y. M., Pan, Y., Wei, Y., Cheng, X., Zhou, B. P., Tan, M., Zhou, X., Xia, W., Hortobagyi, G. N., Yu, D., and Hung, M. C. (2004). Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6, 459-469. Liang, Z., Wu, H., Reddy, S., Zhu, A., Wang, S., Blevins, D., Yoon, Y., Zhang, Y., and Shim, H. (2007). Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 363, 542-546. Liotta, L. A. (2001). An attractive force in metastasis. Nature 410, 24-25. Liotta, L. A. et al. (1976). The Significance of Hematogenous Tumor Cell Clumps in the Metastatic Process Cancer Res 36, 889-894. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56. Muller, V., Witzel, I., Luck, H. J., Kohler, G., von Minckwitz, G., Mobus, V., Sattler, D., Wilczak, W., Loning, T., Janicke, F., et al. (2004). Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86, 9-18. Murakami, T., Maki, W., Cardones, A. R., Fang, H., Tun Kyi, A., Nestle, F. O., and Hwang, S. T. (2002). Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62, 7328-7334. Nicolson, G. L. (1991). Gene expression, cellular diversification and tumor progression to the metastatic phenotype. Bioessays 13, 337-342. Paget, S. (1889). The Distribution Of Secondary Growths In Cancer Of The Breast. Lancet 133, 571-573. Ruifrok, A. C., Katz, R. L., and Johnston, D. A. (2003). Comparison of quantification of histochemical staining by hue-saturation-intensity (HSI) transformation and color-deconvolution. Appl Immunohistochem Mol Morphol 11, 85-91. Saghatchian, M., Guepratte, S., Hacene, K., Neumann, R., Floiras, J. L., and Pichon, M. F. (2004). Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 19, 14-22. Scala, S., Giuliano, P., Ascierto, P. A., Ierano, C., Franco, R., Napolitano, M., Ottaiano, A., Lombardi, M. L., Luongo, M., Simeone, E., et al. (2006). Human melanoma metastases express functional CXCR4. Clin Cancer Res 12, 2427-2433. Schoppmann, S. F., Fenzl, A., Nagy, K., Unger, S., Bayer, G., Geleff, S., Gnant, M., Horvat, R., Jakesz, R., and Birner, P. (2006). VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 139, 839-846. Su, Y. C., Wu, M. T., Huang, C. J., Hou, M. F., Yang, S. F., and Chai, C. Y. (2006). Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast 15, 533-539. Taylor, C. R., and Levenson, R. M. (2006). Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology 49, 411-424. Tuck, A. B. e. a. (1999). Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18, 42437-44246. Van den Eynden, G. G., Van der Auwera, I., Van Laere, S. J., Huygelen, V., Colpaert, C. G., van Dam, P., Dirix, L. Y., Vermeulen, P. B., and Van Marck, E. A. (2006). Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer 95, 1362-1366. Van der Auwera, I., Colpaert, C., Van Marck, E., Vermeulen, P., and Dirix, L. (2006). Lymphangiogenesis in breast cancer. Am J Surg Pathol 30, 1055-1056; author reply 1056-1057. Viale, G., Maiorano, E., Mazzarol, G., Zurrida, S., Galimberti, V., Luini, A., Renne, G., Pruneri, G., Maisonneuve, P., and Veronesi, U. (2001). Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92, 1378-1384. Walker, R. A. (2006). Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I. Histopathology 49, 406-410. Weiss, L. (1992). Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clinical and Experimental Metastasis 10, 191-199. Woo, S. U., Bae, J. W., Kim, C. H., Lee, J. B., and Koo, B. W. (2008). A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 15, 281-285. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40278 | - |
| dc.description.abstract | 惡性腫瘤是台灣地區死亡原因的首位，一旦出現多處的轉移後，則不論使用何種藥物最終都無法控制。因此，癌細胞轉移的抑制對乳癌研究來說是個值得探討的方向。
腫瘤轉移的確切機制到目前為止，仍是未知。從臨床上的觀察，腫瘤發展到一定大小後，轉移的機率就增加。但是，到底轉移的機制是什麼？與腫瘤的生長有相關嗎？什麼樣的因子在控制著它？這些問題目前都還在研究當中。我們從長期觀察乳癌的病人中發現，如果有淋巴結的轉移，那麼之後有其他器官轉移的機率就高很多。因此，淋巴結的轉移可能就是這癌症轉移過程中的第一步，所以，若以淋巴結轉移為模型，就有可能可以進一步了解轉移的機轉。 腫瘤轉移的假說認為，可能有誘導的因子，才能帶領癌細胞進入到淋巴結甚至轉移至其他器官，亦即所謂種子與土壤（seed and soil）的觀念。目前已知可能相關的誘導因子就是stromal-derived factor 1（SDF-1），它與CXC chemokine receptor 4（CXCR4）是單一對應的蛋白質和接受體，在血液學的研究上，它可能擔任著帶領造血幹細胞回到骨髓的作用，因此腫瘤細胞的轉移可能也受該因子的操控。所以，我們假設，當腫瘤有較高的CXCR4表現時，腫瘤會產生淋巴結轉移的機率就會增加。研究的方法為，採取病人的乳癌腫瘤組織，做CXCR4的病理組織免疫染色的比較。依據病患臨床上淋巴結轉移的有無、腫瘤的大小、癌症分期、組織學、荷爾蒙接受體、HER2/neu來做相關的分析。假使假說是成立的，那麼有淋巴結轉移的患者，腫瘤組織會有CXCR4升高的情形。另外，HER2/neu及荷爾蒙接受體，對復發或轉移相關的因子是否藉由CXCR4來作用？與CXCR4的關係也是研究的重點之ㄧ。 收集了2006年一月至十二月在單一醫院內接受乳癌手術的患者。排除証實有遠處轉移、原位癌、腫瘤分期第四期、淋巴結轉移第三期，或者先接受前輔助化療的病患後，總共有80位患者做CXCR4的病理組織免疫染色，經病理科醫師判讀後，由影像分析軟體加以輔助，將染色結果量化後分為高表現組及低表現組，較為客觀的影像分析結果再進行分析比較。 結果顯示，CXCR4在大多數的乳癌組織都有表現，若劃分為高表現與低表現組後進行分析。則發現在全體病患的年齡、腫瘤大小、分期、淋巴結轉移的有無、淋巴結轉移的分期、荷爾蒙接受體，以及HER2/neu 接受體上均無差異。將條件限定在HER2/neu接受體陰性的情況下，則CXCR4的高表現與淋巴結轉移有相關，在統計上有意義。條件限定為荷爾蒙接受體表現為陽性時，CXCR4的高表現也與淋巴結轉移有關。 研究結果顯示，若HER2/neu陰性時，CXCR4的高表現與淋巴結轉移有關，且有統計上的意義，但是HER2/neu陽性時，CXCR4的高表現則會影響淋巴結轉移的程度，因個案數較少，無法呈現出統計上的意義。HER2/neu可能是乳癌轉移的一個重要因子，它與CXCR4之間也有著某種程度的相關，若Her2不表現時，CXCR4就會取而代之，成為轉移，甚至影響腫瘤惡性度的主要因子。 荷爾蒙接受體表現陽性時，CXCR4的過度表現可能也會促進淋巴結的轉移與其他研究部一致，需要進一步探討。大多數的研究，傾向荷爾蒙接受體會促進CXCR4的作用，但有些研究卻同時發現，CXCR4的表現雖然會提高，荷爾蒙卻也同時降低腫瘤細胞的移行能力。所以，荷爾蒙對轉移而言，尚未定論。臨床上長期服用荷爾蒙抑制劑確實能獲得較好的預後，可能是藉由抑制CXCR4的機轉所達成的，仍有待探討。 | zh_TW |
| dc.description.abstract | Purposes of the study: Lymph node metastasis is an important prognostic factor in breast cancer, and lymph node metastasis may be the initial step for further distal metastasis. Therefore, identifying the contributing factors of lymph node metastasis in breast cancer may be helpful to understand the mechanism of metastasis. CXC chemokine receptor 4（CXCR4）is a member of chemokine receptor which is mostly expressed in immune cells. However, many studies report the expression in cancer cell and the relationship between cancer metastasis and CXCR4 expression. So, our study is to identify the correlation between the CXCR4 expression and axillary lymph node metastasis. This study investigate the influence of hormone receptor and HER2/neu expression.
Material and method: Patients who had distal metastasis, T4 or N3 stage breast cancer, predominant ductal carcinoma in situ, received neoadjuvant chemotherapy or no lymph node data available were excluded. Eighty breast cancer patients between January 2006 and December 2006 were enrolled. All patients received the breast surgery and axillary lymph node dissection or sentinel lymph node sampling. Breast cancer tissue fixed with formalin and embedded with paraffin was obtained and stained with anti-CXCR4 antibody (MAB170, R&D system). This immunohistochemistry (IHC) stain result was interpreted by expert pathologists and then analyzed by image analysis software (Image-pro plus Ver 5.1). According to image analysis result of IHC stain, we divide patients into two groups as CXCR4 high and low expression. The results with age, tumor size, lymph node metastasis, estrogen receptor (ER), progesterone receptor (PR), and HER2/neu were examined by chi-square or Fisher’s exact test. Result: There is no significant difference between CXCR4 expression and pathological characteristics. But, there is significant difference between CXCR4 expression and lymph node metastasis in HER2/neu negative (p = 0.04) and hormone receptor positive patients (p = 0.02 in ER and p = 0.03 in PR). Conclusion: Our finding is that CXCR4 high expression contributes to axillary lymph node metastasis, especially when HER2/neu is negative. In other words, CXCR4 may be an alternative pathway in tumor invasion and metastasis when HER2/neu is not working. Another result is that CXCR4 high expression in hormone receptor positive patient associate with axillary lymph node metastasis. However, the really relationship between hormone receptor and CXCR4 is not quite clear and it needs further study. But, if CXCR4 really has influence on hormone receptor positive cancer cell, maybe that’s the reason why we use hormone therapy could achieve better outcome. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-14T16:43:54Z (GMT). No. of bitstreams: 1 ntu-97-P95421028-1.pdf: 828675 bytes, checksum: c6a6f781b7158fde6f2c388738ae68e5 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 口試委員會審定書 2
誌謝 3 目錄 4 圖表目錄 6 中文摘要 7 英文摘要 9 第一章 研究的背景及目的 11 第一節 腫瘤的轉移 11 第二節 乳癌的淋巴結轉移及遠處轉移 12 第三節 chemokine與腫瘤轉移 14 第四節 荷爾蒙接受體及HER2/neu與腫瘤轉移 15 第二章 研究之材料及方法 16 第一節 病患的篩選 16 第二節 乳癌組織之免疫染色(ER，PR，HER2/neu，及CXCR4) 17 第三節 影像分析軟體判讀 21 第四節 免疫染色結果之定義及分析方法 23 第三章 結果 25 第一節 病患基本資料分析 25 第二節 免疫染色結果 25 第三節 CXCR4表現之高低與淋巴結轉移的相關 25 第四節 CXCR4，荷爾蒙接受體，HER2/neu與淋巴結轉移 26 第四章 討論 27 結論 36 展望 37 圖表 39 參考文獻 52 | |
| dc.language.iso | zh-TW | |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | HER2/neu | zh_TW |
| dc.subject | 轉移 | zh_TW |
| dc.subject | 淋巴結 | zh_TW |
| dc.subject | CXCR4 | zh_TW |
| dc.subject | lymph node | en |
| dc.subject | CXCR4 | en |
| dc.subject | metastasis | en |
| dc.subject | HER2/neu | en |
| dc.subject | breast cancer | en |
| dc.title | CXCR4的高量表現在HER2陰性之乳癌患者會促使淋巴結轉移的發生 | zh_TW |
| dc.title | High expression of CXCR4 in HER2 negative breast cancer patient may contribute to lymph node metastasis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 江伯倫,張金堅,侯明鋒 | |
| dc.subject.keyword | 乳癌,CXCR4,淋巴結,轉移,HER2/neu, | zh_TW |
| dc.subject.keyword | breast cancer,CXCR4,lymph node,metastasis,HER2/neu, | en |
| dc.relation.page | 57 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-08-01 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 809.25 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。